에 대한 최신 뉴스 IGM Biosciences (NASDAQ:IGMS) 주식

IGM Biosciences

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.

Analyst Color

Broad U.S. Equity ETFs

Small Cap

ETFs

EVGO

IGMS

LNTH

MORF

OUST

PLSE

SOUN

iShares Russell 2000 ETF가 추적하는 러셀(Russell) 2000 소형주 지수는 2023년 10월 이후 최고의 주간 실적을 기록하여 6% 이상 급등하여 2022년 1월 이후 최고 수준에 도달했다.

러셀 2000 지수, 연중 가장 강한 주를 기록하며 31개월 최고치를 기록

IGM Biosciences Inc

WIIM

AGRO

Adecoagro shares are trading lower after the company reported worse-than-expected Q3 financial results.

Craig-Hallum analyst Richard Shannon maintains Tower Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSEM#NASDAQ">TSEM</a>) with a Buy and raises the price target from $54 to $60.

News

Price Target

Analyst Ratings

TSEM

Craig-Hallum Maintains Buy on Tower Semiconductor, Raises Price Target to $60

Tower Semiconductor Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSEM#NASDAQ">TSEM</a>) tanked in trading on Thursday, after the company reported <a href="https://www.benzinga.com/news/earnings/24/11/41940062/tower-semiconductor-q3-earnings-revenue-and-profit-beat-plans-350-million-expansion">upbeat third-quarter results</a>.
The company reported strong results and announced higher-than-expected guidance on "aggressive AI-levered demand," according to Benchmark.
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e2ae9e3430dee0001c80e0c/cody-acree">Analyst Cody Acree</a> reiterated a Buy rating on Tower Semiconductor while raising the price target from $55 to $60.
The Tower Semiconductor Thesis: The company reported sales of $371 million and earnings of 57 cents per share, higher than consensus of $370 million and 53 cents per share, respectively, Acree said in the note. &nbsp;
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Tower Semiconductor announced its December quarter revenues about $9 million higher than consensus on robust demand from "its broader RF (Radio Frequency) business, which includes both RF Mobile, RF SOI switches for the smartphone market, and RF Infrastructure demand for Data Center connectivity applications," the analyst stated.
"With solid customer demand increasing for its SiGe and SiPho products for optical transceivers servicing AI Data Center applications, Tower is undertaking a new $350 million capacity expansion initiative, where it is planning to invest in multiple existing factories to significantly increase its ability to meet rapidly increasing customer forecasts," he further wrote.
TSEM Price Action: Shares of Tower Semiconductor had declined by 4.81% to $46.09 at the time of publication on Thursday.
Read More: • <a href="https://www.benzinga.com/24/11/41943233/paymentus-posts-better-than-expected-earnings-joins-dave-honest-company-natera-cava-group-and-other-big-stocks-moving-higher-on-wednesday">Paymentus Posts Better-Than-Expected Earnings, Joins Dave, Honest Company, Natera, CAVA Group And Other Big Stocks Moving Higher On Wednesday</a>
Photo: Shutterstock

Earnings

Earnings Beats

Long Ideas

Reiteration

Movers

Tech

Trading Ideas

Tower Semiconductor Analyst Raises Forecast On 'Aggressive AI-Levered Demand'

Cisco Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) shares are trading lower Thursday following the release of the networking equipment company&#8217;s first-quarter fiscal 2025 results. Here&#8217;s <a href="https://www.benzinga.com/news/earnings/24/11/41955614/cisco-q1-earnings-revenue-beat-eps-beat-strong-start-to-year-customers-investing-in-ai-and-more">what you need to know.</a>
What To Know: Cisco reported revenue of $13.84 billion for the quarter, beating analyst estimates of $13.77 billion. Adjusted earnings per share came in at 91 cents, exceeding the expected 87 cents per share, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. This marks the tenth consecutive quarter that Cisco has topped estimates for revenue and earnings.
Although Cisco beat analyst expectations, total revenue fell 6% year-over-year as product revenue declined 9%, and services revenue increased 6%. The company generated $3.7 billion in cash flow from operations, a 54% increase compared to the same quarter last year, and ended the period with $18.7 billion in cash and investments.
Looking ahead, Cisco anticipates fiscal second-quarter revenue between $13.75 billion and $13.95 billion, and adjusted earnings per share in the range of 89 cents to 91 cents. The company projects full-year 2025 revenue between $55.3 billion and $56.3 billion, and full-year adjusted earnings between $3.60 and $3.66 per share.
"Cisco is off to a strong start to fiscal 2025. Our customers are investing in critical infrastructure to prepare for AI, and with the breadth of our portfolio, we are uniquely positioned to capitalize on this opportunity," said Chuck Robbins, chair and CEO of Cisco.
See Also: <a href="https://www.benzinga.com/24/11/41971559/disneys-q4-boosted-by-streaming-gains-strong-box-office-and-solid-parks-performance">Disney Q4 Earnings: Revenue And Profit Beat, Best Film Studio Performance, 3-Year Outlook And More</a>
Following the earnings report, multiple analysts raised price targets on Cisco stock. 
<ul>
<li>Piper Sandler maintained a Neutral and raised the price target from $52 to $57.</li>
</ul>
<ul>
<li>Morgan Stanley maintained an Overweight and raised the price target from $58 to $62</li>
</ul>
<ul>
<li>Barclays maintained an Equal-Weight and raised the price target from $49 to $56.</li>
</ul>
<ul>
<li>Wells Fargo maintained an Equal-Weight and raises the price target from $57 to $60.</li>
</ul>
<ul>
<li>BofA Securities maintained a Buy and raised the price target from $60 to $72.</li>
</ul>
CSCO Price Action: Cisco shares were down 2.14% at $57.90 at the time of writing, according to<a href="https://pro.benzinga.com/dashboard"> Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="543" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14101956/CSCO-1024x543.png" alt="" class="wp-image-648234" style="width:408px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14101956/CSCO-1024x543.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14101956/CSCO-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14101956/CSCO-768x407.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14101956/CSCO.png 1165w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/41976075/nomad-foods-q3-sales-grow-08-adjusted-ebitda-up-19-lowers-fy24-revenue-growth-outlook-due-to-erp-challenges">Frozen Food Company Nomad Overcomes ERP Hiccups With Solid Q3 Profit Growth, Cools 2024 Expectations</a></li>
</ul>
Image via Shutterstock.

CSCO

Cisco Shares Are Dropping Today: What's Going On?

AFYA

Afya Limited shares are trading lower. The company reported Q3 financial results.

RBC Capital analyst Kenneth Lee maintains Victory Capital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCTR#NASDAQ">VCTR</a>) with a Outperform and raises the price target from $61 to $72.

VCTR

RBC Capital Maintains Outperform on Victory Capital Holdings, Raises Price Target to $72

Suburban Propane Partners shares are trading lower after the company reported worse-than-expected Q4 financial results.

Sensus Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRTS#NASDAQ">SRTS</a>) reported quarterly earnings of $0.07 per share. This is a 177.78 percent increase over losses of $(0.09) per share from the same period last year. The company reported $8.84 million in sales this quarter. This is a 126.76 percent increase over sales of $3.90 million the same period last year.

SRTS

Sensus Healthcare Q3 EPS $0.07 Up From $(0.09) YoY, Sales $8.84M Up From $3.90M YoY

RBC Capital analyst Gregory Renza maintains Viracta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRX#NASDAQ">VIRX</a>) with a Outperform and lowers the price target from $4 to $2.

VIRX

RBC Capital Maintains Outperform on Viracta Therapeutics, Lowers Price Target to $2

Macro Economic Events

Market Summary

Economics

General

Benzinga Market Summary: Disney Surges On Strong Q4 Results, S&P Falls Slightly, PPI Figures Fall Relatively In Line With Estimates

Craig-Hallum analyst George Sutton maintains Hut 8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) with a Buy and raises the price target from $15 to $32.

Craig-Hallum Maintains Buy on Hut 8, Raises Price Target to $32

SPIR

Spire Global shares are trading higher after Craig-Hallum upgraded the stock from Hold to Buy and raised its price target from $8 to $20. Also, Baird raised its price target from $9 to $16.

PDSB

PDS Biotechnology shares are trading lower after the company reported worse-than-expected Q3 financial results.

<a href="https://www.barrons.com/articles/citigroups-probe-russian-oligarch-kerimov-c10cfa2e">https://www.barrons.com/articles/citigroups-probe-russian-oligarch-kerimov-c10cfa2e</a>
<a href="https://www.barrons.com/market-data/stocks/c?mod=article_chiclet">Citigroup</a> is being investigated by several U.S. agencies for the work it has done for a trust that holds the assets of Suleiman Abusaidovich Kerimov, a Russian official sanctioned by the U.S. government, as federal officials continue to scrutinize how Russia's oligarchs store and access their assets abroad.
The Department of Justice, the Federal Bureau of Investigation, and the Internal Revenue Service have been investigating the matter for more than a year, a person with knowledge of the situation said.
The probe centers on <a href="https://www.barrons.com/market-data/stocks/c?mod=article_chiclet">Citigroup</a>
<a href="https://www.barrons.com/market-data/stocks/c?mod=article_chiclet">C</a>
<a href="https://www.barrons.com/market-data/stocks/c?mod=article_chiclet">-0.91%</a>
providing services to Heritage Trust, which held the assets of <a href="https://www.wsj.com/articles/u-s-targets-russian-oligarchs-in-new-sanctions-1523018826?mod=article_inline">Kerimov</a>, an ally of Russian President Vladimir Putin who made his fortune in the Russian gold mining industry. The U.S. government has <a href="https://home.treasury.gov/news/press-releases/jy0841">said</a> the trust was formed seven years ago to hold and manage Kerimov's U.S.-based assets.
&nbsp;
The probe also focuses on Citi's financial compliance framework, such as the anti-money-laundering and client-vetting processes designed to prevent financial crimes. While Citi's trust business still has the Heritage Trust account on its books, the bank cannot administer it as a typical trust—by distributing or accepting funds—while it is blocked by the Treasury Department.
"Citi is committed to conducting all business with the highest consideration for compliance with all applicable laws and regulations," the Citi spokesperson said in a statement to Barron's. "At the same time, we are actively ending nearly all of our institutional banking business in Russia, except for those operations necessary to fulfill remaining legal and regulatory obligations, while we proceed with the closing of our Russian consumer banking business."
Kerimov and his representatives were unable to be reached by Barron's. The Justice Department declined to comment. The IRS and FBI didn't provide comment. Clifford Chance, the law firm Citi hired as outside counsel, declined to comment.
Kerimov is the world's 293rd-richest person, according to the 500-person <a href="https://www.bloomberg.com/billionaires/profiles/suleiman-a-kerimov/">Bloomberg Billionaires Index</a>, with a net worth of nearly $10 billion. The U.S. said it <a href="https://home.treasury.gov/news/press-releases/sm0338">imposed sanctions</a> on Kerimov in 2018 for being an official of the Government of the Russian Federation. Kerimov was also sanctioned by the European Union, Japan, and other countries.
Two years ago the Treasury Department <a href="https://home.treasury.gov/news/press-releases/jy0841">blocked</a> Kerimov from accessing Heritage Trust, which held $1 billion as of June 2022, as part of an investigation into the oligarch's "use of a network of relatives, advisors, and opaque legal entities to invest in the United States." That year, the Justice Department ordered the <a href="https://www.justice.gov/opa/pr/300-million-yacht-sanctioned-russian-oligarch-suleiman-kerimov-seized-fiji-request-united">seizure</a> of a superyacht that it alleged was owned by Kerimov and subject to forfeiture over probable cause of U.S. law violations, including money laundering and conspiracy.
Citi offers trust and wealth planning services to rich clients through its private bank, which is part of the wealth management division. The bank is in the process of <a href="https://www.barrons.com/articles/citigroup-sale-trust-unit-jtc-0bbf04e1?mod=article_inline">selling its trust unit</a> to JTC, a firm based on the English Channel island of Jersey that has expanded in the U.S. through acquisitions, for $80 million. Citi's wealth arm manages $580 billion of investment assets. JTC declined to comment.
Citi is facing federal scrutiny over issues with its internal controls. The Office of the Comptroller of the Currency and the Federal Reserve <a href="https://www.barrons.com/articles/bank-regulators-fine-citi-e3b08ee6?mod=article_inline">fined Citi in July</a> after the regulators found the bank hadn't made enough progress in remedying four-year-old consent orders tied to insufficient risk management oversight.
Chief Executive Officer Jane Fraser said in July that "despite making good progress in simplifying our firm" and addressing the consent orders, "there are areas where we have not made progress quickly enough, such as in our data quality management." The bank has "intensified our focus and increased our investment in those areas over the last several months," she said.
Under Fraser, who has led the fourth-largest U.S. lender since March 2021, Citi is aiming to engineer a turnaround after years of problems with financial regulators, poor returns, and high-profile missteps.
Until the Treasury Department prevented Kerimov from accessing Heritage Trust in 2022, Kerimov used "a complex series of legal structures to continue to retain an interest in, and benefit from, his over $1 billion in assets in the United States," said Andrea Gacki, director of the Treasury's Financial Crimes Enforcement bureau, in a <a href="https://www.fincen.gov/news/speeches/prepared-remarks-fincen-director-andrea-gacki-during-beneficial-ownership-1">speech</a> this past August.
"These funds were invested in large public and private U.S. companies and managed by a series of U.S. investment firms and facilitators," Gacki said. "Along the way, Kerimov and his proxies used various layers of shell companies, including [limited liability companies], to conceal his interest."
The probe of the bank and Kerimov comes as the U.S. government continues to <a href="https://www.wsj.com/articles/prosecutors-targeting-russian-oligarchs-shift-focus-to-service-providers-that-support-them-11669767556?mod=article_inline">investigate the ecosystem of service providers</a>, including financial firms, that the government alleges enable Russian oligarchs to move their money and evade sanctions. In March 2022, following Russia's invasion of Ukraine, the Justice Department formed a task force with other U.S. agencies, including the FBI and the IRS, to enforce sanctions and take action against Russian oligarchs.

Global

'Citigroup's Ties To Russian Oligarch Kerimov Draw Federal Scrutiny' - Barron's

RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) with a Sector Perform and raises the price target from $72 to $80.

INCY

RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $80

Turning Point Brands shares are trading higher after the company announced a joint venture with the Tucker Carlson Network. Also, Oppenheimer initiated coverage on the stock with an Outperform rating and announced a price target of $65.

Craig-Hallum analyst Greg Palm maintains Stratasys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSYS#NASDAQ">SSYS</a>) with a Buy and raises the price target from $12 to $15.

SSYS

Craig-Hallum Maintains Buy on Stratasys, Raises Price Target to $15

GORV

Lazydays Holdings Shares Resume Trade Then Again Halt On Circuit Breaker To The Downside, Stock Now up 70.7%

RBC Capital analyst Ken Herbert reiterates Loar Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOAR#NYSE">LOAR</a>) with a Outperform and maintains $100 price target.

LOAR

RBC Capital Reiterates Outperform on Loar Holdings, Maintains $100 Price Target

APEI

American Public Education shares are trading lower. Truist Securities maintained a Hold rating on the stock.

Wedbush analyst Robert Driscoll maintained a Buy rating on IGM Biosciences (IGMS – Research Report) today and set a price target of $22.00. The com...

IGM Biosciences (IGMS) Receives a Buy from Wedbush

IGM Biosciences downgraded to Hold, stock falls

IGM Biosciences ( ($IGMS) ) just unveiled an update. IGM Biosciences, Inc. is refocusing its efforts from oncology to the development of T cell eng...

IGM Biosciences Shifts Focus to Autoimmunity, Appoints New CEO

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Intuitive Surgical (ISRG – Research Report) and IGM ...

Analysts' Top Healthcare Picks: Intuitive Surgical (ISRG), IGM Biosciences (IGMS)

IGM Biosciences GAAP EPS of -$1.01 misses by $0.19, revenue of $0.52M beats by $0.28M

Igm Biosciences ( ($IGMS) ) has released its Q3 earnings. Here is a breakdown of the information Igm Biosciences presented to its investors. IGM Bi...

IGM Biosciences Shifts Focus to Autoimmunity

Igm Biosciences (IGMS) has disclosed a new risk, in the Share Price & Shareholder Rights category. Igm Biosciences faces significant risks that cou...

Igm Biosciences: Navigating Financial Challenges Amidst Early-Stage Antibody Development

Analyst Michael Ulz of Morgan Stanley maintained a Hold rating on IGM Biosciences (IGMS – Research Report), retaining the price target of $12.00. M...

Cautious Outlook for IGM Biosciences Amid Delayed Data and Financial Adjustments

Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on IGM Biosciences (IGMS – Research Report) today and set a price target of $27.00. ...

Stifel Nicolaus Remains a Buy on IGM Biosciences (IGMS)

Stifel raised the firm's price target on IGM Biosciences (IGMS) to $27 from $25 and keeps a Buy rating on the shares. The firm believes management'...

IGM Biosciences price target raised to $27 from $25 at Stifel

ISRG

Health Care

Press Releases

IGM Biosciences Announces Refocusing of Sanofi Collaboration

IGM Biosciences to Present at the 2024 RBCCM Global Healthcare Conference

IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update

Treatment.com AI Inc. (TRUE.CN) Advances AI in Healthcare with Strategic Moves

IGM Biosciences to Present at the Jefferies Healthcare Conference

IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update

IGM Biosciences to Present at the Stifel 2024 Virtual Immunology and Inflammation Summit

IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity

IGM Biosciences to Present at Three Upcoming Investor Conferences

IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update

AKTS

BNED

CSE:TRUE

GWAV

Abivax

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics

Altimmune

AnaptysBio

Annexon

Astria Therapeutics

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

Exscientia Plc - American Depositary Shares

Exscientia

Humacyte

Immunome

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

Mereo BioPharma Group plc - American Depositary Shares

Mereo BioPharma Group

Neurogene

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Opthea Limited - American Depositary Shares

Opthea

Organogenesis Hldgs

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Sana Biotechnology

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics

Stoke Therapeutics

Tectonic Therapeutic, Inc. - Common Stock

Tectonic Therapeutic

Tourmaline Bio

Y-mAbs Therapeutics

Stifel

RBC Capital

Guggenheim

Wedbush

JP Morgan

iShares Russell 2000 ETF가 추적하는 러셀(Russell) 2000 소형주 지수는 2023년 10월 이후 최고의 주간 실적을 기록하여 6% 이상 급등하여 <a href="https://www.benzinga.com/topic/small-caps" target="_blank" rel="noopener" data-google-interstitial="false">2022년 1월 이후</a> 최고 수준에 도달했다.
이러한 랠리는 주로 목요일 세션에 의해 주도되었으며, 러셀 2000 지수는 일일 3.6%라는 놀라운 상승률을 기록했다. 이번 급등은 예상보다 낮은 6월 인플레이션 데이터에 따른 것이며, 이로 인해 잠재적인 금리 인하 가능성에 대한 기대가 강화되었다.
그러나 LPL 파이낸셜의 최고 글로벌 전략가인 퀸시 크로스비(Quincy Krosby)는 러셀 2000의 금리 인하 메시지가 &#8220;노동 시장에 대한 연방준비제도(연준)의 우려로 인해 흐려질 수 있다&#8221;고 시사하면서 주의를 조언했다.
크로스비는 노동시장 약화가 경제적으로 민감한 러셀 2000 지수에 여전히 타격을 줄 것이며, 금리 인하가 반드시 더 광범위한 경기 둔화로부터 지수를 보호할 수는 없을 것이라고 생각한다.
<h2 class="wp-block-heading">이번 주의 차트: 8개월 만에 최대 성과를 올린 소형주 지수</h2>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" class="wp-image-434094" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21-1024x488.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21-1024x488.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21-300x143.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21-768x366.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21-1536x732.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21.png 1920w" alt="" width="1024" height="488" /></figure>
출처: <a href="URL http://www.benzinga.com/pro/register/?utm_source=BZprocontent071224&amp;t=be2bearmibe3na1">Benzinga Pro</a>
러셀 2000의 인상적인 성과는 투자자들이 거대 기술 기업들에서 벗어나 더 넓은 시장으로 직접 유입됨에 따라 금리에 민감한 중소형주가 이익을 얻는 등 시장 초점의 상당한 변화를 강조한다고 크로스비가 강조했다.
이 분석가는 러셀 2000이 잠재적인 금리 완화와 광범위한 경제 상황에 대한 중요한 지표 역할을 한다고 지적했다. 일반적으로 중소형주 유니버스는 매력적인 밸류에이션에도 불구하고 심각한 경기 둔화 조짐이 보이면 매도할 것이다.
"역사적으로 러셀 2000은 첫 번째 금리 인하 이후 3개월 동안 시장보다 뒤쳐졌다. 연준이 일반적으로 경제, 특히 노동 시장에 대한 우려로 금리를 인하하기 때문이다. 파월 의장은 연준의 최대 고용 의무화를 계속해서 주장하면서 연준이 경제 지원을 위해 더 빠른 속도로 금리를 인하할 것이라는 점을 분명히 했다"고 그녀가 말했다.
노동 시장 상황이 악화되면 연준은 예정된 9월 18일 회의보다 더 빨리 완화 주기를 시작할 수도 있다고 크로스비는 말했다. 시장에서는 경기 호조 속에서 인플레이션 완화에 따른 금리 인하를 선호하고 있다.
<h2 class="wp-block-heading">이번 주 러셀 2000에서 가장 높은 성과를 기록한 상위 10개 회사 </h2>
<ol>
<li>모픽 홀딩 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MORF#NASDAQ">MORF</a>): 75.16% (헬스케어)</li>
<li>랜티우스 홀딩스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>): 55.47% (헬스케어)</li>
<li>IGM 바이오사이언스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IGMS#NASDAQ">IGMS</a>): 54.22% (헬스케어)</li>
<li>사운드하운드 AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>): 52.63% (정보기술)</li>
<li>메소드 일렉트로닉스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEI#NASDAQ">MEI</a>): 47.96% (정보기술)</li>
<li>솔라리스 오일필드 인프라스트럭처 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOI#NYSE">SOI</a>): 46.87% (에너지)</li>
<li>펄스 바이오사이언스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>): 45.98% (헬스케어)</li>
<li>아우스터 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NYSE">OUST</a>): 44.21% (정보기술)</li>
<li>EV고 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>): 42.65% (소비자 자유롭게 선택 가능한 소비재)</li>
<li>선런 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>): 42.51% (산업재)</li>
</ol>
지금 읽기:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/07/39750466/us-consumer-morale-dips-more-than-expected-in-july-sentiment-remains-stubbornly-subdued">미국 소비자 심리, 7월 예상보다 감소&#8230;전망은 &#8216;완고하게 억제된 상태&#8217;</a></li>
</ul>
사진: 셔터스톡
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

IGM Biosciences

뉴스

에 대한 최신 뉴스 IGM Biosciences (NASDAQ:IGMS) 주식

금요일, 7월 12, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌